Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease.

Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease.

At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.

Lyterian Therapeutics

Ingrid Wertz

Veronica Kuiper

Teams at Lyterian Therapeutics

Research and Development

Leadership Team